C07D 239/93
Sulfur atoms
C07D239/93 (Sulfur atoms) appears on 71 US grants and 48 published applications in this corpus.
Search patents in C07D- Granted patents
- 71
- Published applications
- 48
- Assignees
- 58
- Inventors
- 191
- Latest grant
- 28 Jul 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 2 | 0 |
| 1977 | 0 | 0 |
| 1978 | 1 | 0 |
| 1979 | 0 | 0 |
| 1980 | 0 | 0 |
| 1981 | 1 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 1 | 0 |
| 1988 | 0 | 0 |
| 1989 | 1 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 1 | 0 |
| 1993 | 1 | 0 |
| 1994 | 3 | 0 |
| 1995 | 3 | 0 |
| 1996 | 2 | 0 |
| 1997 | 1 | 0 |
| 1998 | 10 | 0 |
| 1999 | 2 | 0 |
| 2000 | 3 | 0 |
| 2001 | 4 | 0 |
| 2002 | 2 | 3 |
| 2003 | 2 | 2 |
| 2004 | 0 | 1 |
| 2005 | 1 | 2 |
| 2006 | 0 | 3 |
| 2007 | 0 | 0 |
| 2008 | 1 | 1 |
| 2009 | 0 | 2 |
| 2010 | 3 | 4 |
| 2011 | 1 | 4 |
| 2012 | 0 | 3 |
| 2013 | 3 | 3 |
| 2014 | 3 | 2 |
| 2015 | 3 | 1 |
| 2016 | 2 | 3 |
| 2017 | 4 | 4 |
| 2018 | 1 | 4 |
| 2019 | 1 | 1 |
| 2020 | 3 | 2 |
| 2021 | 1 | 0 |
| 2022 | 2 | 0 |
| 2023 | 0 | 3 |
| 2024 | 0 | 0 |
| 2025 | 0 | 0 |
| 2026 | 2 | 0 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Methods and compositions for targeting Tregs using CCR8 inhibitors28 Jul 2026US 12,692,239 B2Nanjing Immunophage Biomedical Co., Ltd.
- Methods and compositions for targeting Tregs using CCR8 inhibitors17 Feb 2026US 12,552,753 B2Nanjing Immunophage Biomedical Co., Ltd.
- Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies1 Mar 2022US 11,261,199 B2NY State Psychiatric Institute
- Activators of autophagic flux and phospholipase D and clearance of protein aggregates including tau and treatment of proteinopathies25 Jan 2022US 11,230,558 B2NY State Psychiatric Institute
- Activators of autophagic flux and phospholipase D and clearance of protein aggregates including tau and treatment of proteinopathies18 May 2021US 11,008,341 B2NY State Psychiatric Institute
- Methods and Compositions for Targeting Tregs using CCR8 Inhibitors25 May 2023US 2023/0159446 A1Nanjing Immunophage Biomedical Co., Ltd.
- 2,3-dihydroquinazolin compounds as nav1.8 inhibitors6 Apr 2023US 2023/0103791 A1GlaxoSmithKline Intellectual Property Development Limited
- Methods and compositions for targeting Tregs using CCR8 inhibitors9 Feb 2023US 2023/0038589 A1Nanjing Immunophage Biotech Co., Ltd.
- Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies9 Jul 2020US 2020/0216469 A1NY State Psychiatric Institute
- Novel anti-inflammatory agents30 Apr 2020US 2020/0129512 A1Resverlogix Corp.
Most cited
By later US patents
- Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase226US 5,480,883 ARhone-Poulenc Rorer Pharmaceuticals Inc. · 1996
- Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase209US 5,409,930 ARhone-Poulenc Rorer Pharmaceuticals Inc. · 1995
- Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase198US 5,710,158 ARhone-Poulenc Rorer Pharmaceuticals Inc. · 1998
- Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase171US 5,646,153 ARhone-Poulenc Rorer Pharmaceuticals Inc. · 1997
- Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties144US 5,721,237 ARhone-Poulenc Rorer Pharmaceuticals Inc. · 1998